Navigation Links
IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting

t non-small cell lung cancer, or NSCLC. The trial design was an open label, non-placebo trial with one year follow-up for survival. Sixty-four patients were enrolled in the trial with the last patient enrolled in March 2006.

About UVIDEM(R)

UVIDEM is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. Sanofi-aventis has worldwide marketing rights to UVIDEM in melanoma. UVIDEM consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. UVIDEM is produced in IDM Pharma GMP manufacturing facilities in Irvine, California and in Paris, France. UVIDEM has been administered to 143 patients in clinical development. Completion of patient enrollment in two Phase II clinical trials was previously announced. Thirty-eight patients with malignant melanoma were included in the US Phase II study and 53 patients with resected stage II/III melanoma were included in the European randomized Phase II study.

About EP-2101

The EP-2101 cancer vaccine candidate used in this trial includes nine CTL epitopes from four tumor associated antigens (TAA) including two proprietary native epitopes and seven modified, or analog, epitopes. Tolerance to TAA, which is a failure of the immune system to recognize the cancer as diseased tissue, is broken by using these analog epitopes which enhance the potency of the T cell response. PADRE(R), a universal HTL epitope we have licensed from Pharmexa, is also included in the vaccine as an immunostimulant. The phase II EP-2101 study has been ongoing since late 2004.

About Melanoma

According to the American Cancer Society, in 2007 approximately 59,940 new cases are expected to be diagnosed and it is estimated that approximately 8,110 people in the United Sates will die from the disease.

About Lung Cancer

Cancer of the lungs continues to be a major health problem with a very high mortality rate and represents the leading cause of canc
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:3/27/2015)... YORK , March 27, 2015 BioCorRx, ... Santa Ana, California is a healthcare ... for which is estimated at $22 billion in the U.S. ... the use of FDA-approved Naltrexone in a specially compounded form ... Australia and New Zealand ...
(Date:3/27/2015)... March 27, 2015 Across the global healthcare ... challenges in clinical development, market education, and regulatory compliance. ... Medical Affairs function is expected to increase in prominence ... According to research by benchmarking firm, Best ... group dedicated to Medical Affairs. Among companies in ...
(Date:3/27/2015)... 2015  The quality function within the medical device ... quality standards at every stage of the product life ... also have the challenge of balancing quality and safety ... don,t effectively balance these priorities risk funding and staffing ... and regulatory scrutiny. For the third consecutive ...
Breaking Medicine Technology:Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Medical Affairs Capabilities Expanding in Emerging Marketplaces 2New Medical Device Quality Study Finds Regulatory Environment is Boosting Quality Spending, Especially for Large Companies 2
... Clinical trials in which participants are randomly assigned to different ... conducted correctly, it,s widely accepted by the research community that ... But researchers at the University of Michigan hope to ... patients by investigating the impact of a class of innovative ...
... CRY ), an implantable biological medical device ... BioGlue Surgical Adhesive has received Shonin approval from the ... use in the repair of aortic dissections. ... in Japan for use in this subset of cardiac ...
Cached Medicine Technology:U-M Receives NIH, FDA Grant To Study Adaptive Clinical Trial Design 2CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive 2CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive 3CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive 4CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive 5
(Date:3/28/2015)... AZ (PRWEB) March 28, 2015 Coffee could ... also help protect you from gum disease, researchers have found. ... against gum disease. , Coffee contains antioxidants. Antioxidants fight gum ... the question researchers at Boston Univ. Henry M. Goldman School ... in the August 2014 issue of the Journal of Periodontology. ...
(Date:3/28/2015)... March 28, 2015 Could genetic code ... new study by researchers at the Harvard ... with the support of the Coffee and Caffeine Genetics ... Psychiatry this past fall, the study—one of several recent ... genomic data from more than 120,000 regular coffee drinkers ...
(Date:3/28/2015)... "Necrorun" was featured on NewsWatch as part ... the latest and coolest applications on the market for ... NewsWatch and technology expert, conducted the app review and ... runner game with knights, nature, and peasants. , ... according to Eurogamer. The popularity of these games grew ...
(Date:3/28/2015)... Take a bite of warm, gooey pepperoni ... tumble into the stomach, ready to break down your ... these acids run amok, triggering a burning sensation in ... than 60 million Americans have heartburn at least once ... and how it can be stopped. , Heartburn or ...
(Date:3/28/2015)... 28, 2015 With more than ... fields of osteoporosis, osteoarthritis and musculoskeletal diseases gathered ... may be the first time in the 17-year ... that the hot-button topic is an emerging non-pharmaceutical ... well-accepted scientific principles of Wolff’s law, osteogenic loading ...
Breaking Medicine News(10 mins):Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2
... BeneChill, Inc. ( www.benechill.com ) today announced the ... study. This randomized study will determine whether intra-nasal ... patient resuscitation and survival rates.The PRINCE study is ... Europe. The company received CE marking for the ...
... manufacturer of,GUM(R) and Butler(R) brand products and a leader ... worldwide, is putting its support,behind the American Dental Association,s ... health. , Each February since ... to raise awareness about the importance of oral health. ...
... most symptoms fade within 6 weeks, experts say , , ... physical therapy and anti-inflammatory drugs is the most effective ... degenerative disc disease, according to a review of published ... 90 percent of people with low back pain, symptoms ...
... part in regular physical activity have a better quality ... issue of the journal Cancer Epidemiology Biomarkers and ... more physically active report better mood, more vigor, and ... take-home message is that early-stage lung cancer survivors may ...
... ANN ARBOR, Mich. One-fifth of women who should ... potentially lifesaving treatment, according to a new study from ... , The study looked at 396 women who were ... found that 19 percent of women who fell clearly ...
... Vitamin(R) has launched the web site for Keep ,Em ... that gives pregnant women the greatest opportunity to carry ... information and offering online community support. , ... Cookin, with one very specific goal in mind --- ...
Cached Medicine News:Health News:BeneChill Launches European Study of Intra-Arrest Cooling 2Health News:Sunstar to Support ADA's 60th Annual National Children's Dental Health Month 2Health News:Sunstar to Support ADA's 60th Annual National Children's Dental Health Month 3Health News:Therapy, Meds Best for Lumbar Low Back Pain 2Health News:Regular physical activity linked to better quality of life in early-stage lung cancer survivors 2Health News:19 percent of breast cancer patients don’t receive recommended radiation after mastectomy 2Health News:Vitamin Launches Online Face for Keep 'Em Cookin' 2
Benchtop UV Incubator is designed to provide precise temperature control and uniformity throughout the chamber. Decontaminate chamber between experiments with built-in shortwave UV....
Inquire...
Inquire...
Inquire...
Medicine Products: